Business, energy, technology, markets and global industry news from Business News Today

gastroesophageal junction cancer

PharmaDeviceNews gastroesophageal junction cancer
Representative image of oncologists reviewing advanced gastric cancer imaging in a modern cancer care setting, reflecting Ono Pharmaceutical’s ONO-4578 Phase 2 data and the race to improve first-line treatment for HER2-negative gastric and gastroesophageal junction cancer.
Pharma & Biotech

Can Ono and Deciphera turn ONO-4578 into a global Phase 3 oncology contender?

Ono’s ONO-4578 improved gastric cancer PFS in Phase 2. The next test is whether EP4 blockade can survive global Phase 3 scrutiny.

Read More
Representative image of oncology biomarker testing and antibody-drug conjugate research. Antengene’s ATG-022 Phase III clearance highlights rising competition in CLDN18.2-targeted treatment for advanced gastric and gastroesophageal junction cancer.
Pharma & Biotech

Why CLINCH-3 matters for Antengene’s oncology strategy and gastric cancer ambitions

Antengene’s ATG-022 enters pivotal testing in gastric cancer, testing whether CLDN18.2 ADCs can stand out in a crowded oncology field.

Read More
Pharma & Biotech

Akeso’s cadonilimab outperforms PD-1 inhibitors in real-world gastric cancer study

Cadonilimab outperforms PD-1 inhibitors in PD-L1-low gastric cancer patients. Find out what this means for global immunotherapy standards.

Read More